Saturn V Capital Management »

Vir Biotechnology shares owned by Saturn V Capital Management

Quarter-by-quarter ownership of Vir Biotechnology (VIR) shares owned by Saturn V Capital Management from 13F filings

Historical chart of Saturn V Capital Management investment in Vir Biotechnology

Tip: Access up to 7 years of quarterly data

All positions including Vir Biotechnology held by Saturn V Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Vir Biotechnology by Saturn V Capital Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $7.9M 771k 10.19

More positions owned by Saturn V Capital Management

Amylyx Pharmaceuticals (AMLX)
Alumis (ALMS)
Abivax Sa Sponsored Ads (ABVX)
Vaxcyte (PCVX)
Immix Biopharma (IMMX)
Pharvaris N V (PHVS)
Jazz Pharmaceuticals Shs Usd (JAZZ)
Celcuity (CELC)
Disc Medicine (IRON)
Candel Therapeutics (CADL)
X4 Pharmaceuticals Com New (XFOR)
Monopar Therapeutics Com New (MNPR)
Dyne Therapeutics (DYN)
Trevi Therapeutics (TRVI)
Zura Bio Class A Ord Shs (ZURA)

View all positions for Saturn V Capital Management

Top funds holding Vir Biotechnology

BlackRock
Arch Venture Corp
Vanguard Portfolio Management
Sb Investment Advisers
GSK
State Street Corporation
Vanguard Capital Management
Point72 Asset Management
Geode Capital Management
Dimensional Fund Advisors
Morgan Stanley
ADAR1 Capital Management
Goldman Sachs Group
FMR
Nuveen

View all funds holding Vir Biotechnology